-
Registration Now Open for Tribe Public CEO Presentation and Q&A Webinar Event
“Ebola, Marburg, Hantavirus, Mpox and Beyond: Building a Resilient Infectious Disease Preparedness Strategy” Featuring GeoVax CEO David Dodd on May 28, 2026 Meet…
-
GeoVax Accelerates Focus on GEO-MVA Commercialization and Advancement of Oncology Program Gedeptin(R)
Company Aligns Resources with Programs Demonstrating Strong Clinical, Regulatory, and Market Momentum ATLANTA, GA — May 26, 2026 — GeoVax Labs, Inc. (Nasdaq: GOVX),…
-
GeoVax Comments on Escalating Bundibugyo Ebola Outbreak and Growing Need for Flexible Biodefense Vaccine Platforms
Company Highlights Potential Role of MVA-Based Vaccine Technologies in Addressing Emerging Hemorrhagic Fever Threats, Including Ebola and Marburg Viruses ATLANTA, GA – May…
-
GeoVax Highlights Strategic Importance of Domestic MVA-Based Preparedness Infrastructure Amid Escalating Global Infectious Disease Threats
WHO Emergency Declaration of Ebola Outbreak and Ongoing Mpox Developments Reinforce the Importance of Diversified Vaccine Supply and Scalable U.S.-Based Manufacturing Capabilities ATLANTA,…
-
GeoVax Announces $3 Million Private Placement Financing Priced At-the-Market Under Nasdaq Rules
ATLANTA, GA – May 18, 2026 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies, today announced that it has entered…
-
GeoVax Reports First Quarter 2026 Financial Results and Highlights GEO-MVA Phase 3 Trial Implementation Plans
ATLANTA, GA, May 14, 2026 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies against infectious diseases and cancer,…
-
GeoVax Highlights Emerging Role of Gedeptin® in Combination Immunotherapy Strategies Targeting Immunologically “Cold” Tumors
Company Expands Strategic Immuno-Oncology Positioning Around Tumor Microenvironment Modulation, Checkpoint Enhancement, and Multi-Tumor Development Potential ATLANTA, GA – May 13, 2026 – GeoVax Labs, Inc. (Nasdaq:…
-
GeoVax Announces a Warrant Inducement Transaction
ATLANTA, GA – May 7, 2026 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies, today announced its entry…
-
GeoVax Initiates Phase 3 Execution Activities for GEO-MVA Under EMA-Aligned Immunobridging Pathway
Company Advances to Active Clinical Execution, Supporting Potential Accelerated Path Toward Regulatory Authorization ATLANTA, GA – May 6, 2026 – GeoVax Labs, Inc. (Nasdaq:…
-
GeoVax Advances Gedeptin® Toward Phase 2 Initiation and Strategic Partnership Opportunities
Near-Term Clinical Milestones and Combination Strategy Position Program for Next Stage of Value Creation ATLANTA, GA – April 29, 2026 – GeoVax Labs, Inc.…
-
GeoVax Highlights Gedeptin® as a Potential Immune-Sensitizing Platform Amid Rising Industry Investment in In Vivo Cancer Therapies
Positioned to Enhance Efficacy of Checkpoint Inhibitors and Next-Generation Oncology Modalities Across Solid Tumors ATLANTA, GA – April 27, 2026 – GeoVax Labs, Inc.…
-
GeoVax Reports 2025 Year-End Financial Results and Provides Business Update
Pivotal Phase 3 Trial for GEO-MVA (Mpox/Smallpox Vaccine) Scheduled to Initiate During the Second Half of This Year ATLANTA, GA, April 15, 2026 – GeoVax…